Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells

Hematology

Volumn 16, Issue 1, 2011, Pages 24-30

  Chen, Baoan ^a   Yin, Li ^a   Cheng, Jian ^a   Ding, Jiahua ^a   Gao, Chong ^a   Sun, Yunyu ^a   Zhao, Gang ^a   Wang, Jun ^a   Bao, Wen ^a   Xia, Guohua ^a   Gao, Feng ^a   Wang, Xuemei ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Ceramide glucosyltransferase; Multidrug resistance; P glycoprotein; PDMP; Tetrandrine

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; DAUNORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; TETRANDRINE;

ARTICLE; CELL LINE; CELL STRAIN K 562/A 02; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CORRELATION ANALYSIS; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZYLISOQUINOLINES; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; K562 CELLS; LEUKEMIA; MORPHOLINES;

EID: 79551698384     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X12902908411797     Document Type: Article

References (27)

1. Volm M, Kästel M, Mattern J, Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993;71:3981-7.
2. Lala P, Ito S, Lingwood CA. Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of P-glycoprotein in glycolipid synthesis. J Biol Chem 2000;275:6246-51.
3. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206:169-80.
4. Uchida Y, Itoh M, Taguchi Y, Yamaoka S, Umehara H, Ichikawa S, et al. Ceramide reduction and transcriptional upregulation of glucosylceramide synthase through doxorubicinactivated Sp1 in drug-resistant HL-60/ADR cells. Cancer Res 2004;64:6271-9.
5. Gouazé V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 2004;3:633-9.
6. Di Sano F, Di Bartolomeo S, Fazi B, Fiorentini C,Matarrese P, Spinedi A, et al. Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis. Cell Death Differ 2002;9:693-5.
7. Deng W, Li R, Guerrera M, Liu Y, Ladisch S. Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology 2002;12:145-52.
8. Gouazé V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 2005;65:3861-7.
9. Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 2004;53:349-56.
10. Zhao QX, Chen BA, Cheng J, Ding JH, Gao F, Gao C, et al. Effect of tetrandrine, Toremifene and their combination on the reversion of multidrug resistance of K562/A02 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:61-4.
11. Shen H, Xu W, Chen Q, Wu Z, Tang H, Wang F. Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription. J Cancer Res Clin Oncol 2010;136:659-65.
12. Xu WL, Shen HL, Ao ZF, Chen BA, Xia W, Gao F, et al. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res 2006;30:407-13.
13. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem 1999;274:14662-9.
14. SietsmaH, Veldman RJ,KolkD, Ausema B, Nijhof W, KampsW, et al. 1-phenyl-2-ecanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res 2000;6:942-8.
15. Deng W, Li R, Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 2000;92:912-7.
16. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Nat Cancer Inst 2001;93:347-57.
17. Inokuchi J, Jimbo M, Momosaki K, Shimeno H, Nagamatsu A, Radin NS. Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res 1990;50:6731-7.
18. Wang JQ, Chen BA, Cheng J, Xu WL, Sun XC. Comparison of reversal effects of 5-bromotetrandrine and tetrandrine on P-glycoprotein-dependent resistance to adriamycin in human lukemia cell line K562/A02. Ai Zheng 2008;27:491-5.
19. Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE, et al. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 2004;45:933-40.
20. Weiss M, Hettmer S, Smith P, Ladisch S. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res 2003;63:3654-8.
21. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993;7:825-31.
22. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995;85:2147-53.
23. Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, Wang J, et al. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 2008;32:475-80. (Pubitemid 351295915)
24. Plo I, LehneG, BeckstrømKJ, MaestreN, Bettaïeb A, Laurent G, et al. Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells. Mol Pharmacol 2002;62:304-12. (Pubitemid 34804110)
25. Halter D, Neumann S, van Dijk SM, Wolthoorn J, de Mazière AM, Vieira OV, et al. Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J Cell Biol 2007;179:101-15. (Pubitemid 47606687)
26. Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 2002;1:205-13.
27. Turzanski J, Grundy M, Shang S, Russell N, Pallis M. Pglycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol 2005;33:62-72.